Leading BioSciences is one of the pharmaceutical industry’s leading companies focused on the Gastrobiome™ and the role that it plays in both human health and medical conditions. We use the term “Gastrobiome” to refer to the gastrointestinal (GI) microenvironment of enzymes, bacteria, nutrients, mucin, mucus, food and other microorganisms residing within the GI tract, as well as the intestinal mucosal barrier, which keeps these safely confined within the intestines.
More than 30 years of groundbreaking scientific research conducted at the University of California at San Diego and other prestigious academic institutions supports the importance of the Gastrobiome to overall human health and highlights the dangerous medical complications that can occur when the Gastrobiome’s intestinal mucosal barrier is disrupted.
Leading BioSciences is leveraging these decades of academic research, as well as 13 years of the company’s own internal efforts, to develop novel therapeutics designed to improve human health through protection of the Gastrobiome.
Our initial focus is accelerating postoperative return of GI function to shorten patients’ length of stay in the hospital. More than six million surgeries are performed in the US each year that have the potential to break down the intestinal mucosal barrier and trigger delayed return of GI function (ileus) and other postoperative complications.